Inadequate glucose control in type 2 diabetes is associated with impaired lung function and with systemic inflammation Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009
Association between continuous positive airway pressure, weight change and glycaemic control in patients with type 2 diabetes Source: Virtual Congress 2020 – Advance in treatments for sleep and breathing disorders and long-term adherence Year: 2020
Cheyne-stokes-respiration is an independent modulator of systolic blood pressure in patients with diabetes mellitus type 2 Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017
Effect of CPAP treatment on endothelial function, inflammatory markers, blood pressure and glucose control in patients with OSAS with emphasis on gender differences Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011
Comparison of pulmonary function in diabetic patients with and without retinopathy and comparing to control group Source: Annual Congress 2009 - Respiratory physiology Year: 2009
Are spirometry indices associated with microvascular complications in type 1 diabetes subjects? Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry Year: 2019
Elevated breath glucose is related to respiratory symptoms and not to disease type, control, duration or complications in diabetes mellitus patients Source: Eur Respir J 2007; 30: Suppl. 51, 365s Year: 2007
Content of total lipids in the exhaled breath condensate in type 1 diabetic mellitus patients with different level HbA1c Source: Eur Respir J 2004; 24: Suppl. 48, 556s Year: 2004
Influence of the glycaemic control [HbA1c] on sleep disorders reported by 261 obese type 2 diabetic patients Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008
Insulin therapy increases airway responsiveness in type 2 diabetes patients Source: Annual Congress 2008 - Cough and airway hyperresponsiveness Year: 2008
Effect of roflumilast (ROF) on glucose levels in patients with COPD and diabetes mellitus type 2 (DM2) Source: Annual Congress 2010 - COPD: management Year: 2010
Is there any characteristics difference between pulmonary tuberculosis patients with and without diabetes mellitus type 2? Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Decline of the lung function and quality of glycemic control in type 2 diabetes mellitus Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013
Changes in lung function in a rodent model of diabetes mellitus Source: International Congress 2018 – New methods and concepts in tests of lung and respiratory muscle function Year: 2018
Study of pulmonary function in type2 diabetes mellitus and its changes with change in duration and glycemic control Source: Annual Congress 2012 - Pathophysiological mechanisms in disease: new insights Year: 2012
COPD prevalence and severity is associated to type 2 diabetes mellitus complications and lack of glycometabolic control Source: Annual Congress 2008 - COPD and comorbidities Year: 2008
Relative risk of type 2 diabetes mellitus complications is increased in non effectively treated OSA patients Source: Eur Respir J 2005; 26: Suppl. 49, 39s Year: 2005
Effect of inhaled human insulin (EXUBERA®; EXU) vs subcutaneous insulin (SC) on lung lining fluid constituents in adults with type 1 diabetes mellitus (T1DM) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Can new criteria for impaired fasting glucose (IFG) replace oral glucose testing (OGT) for cystic fibrosis-related diabetes (CFRD)? Source: Eur Respir J 2004; 24: Suppl. 48, 616s Year: 2004
Altered exercise capacity in children with type 1 diabetes Source: Virtual Congress 2021 – Respiratory physiology and breathing during sleep in health and sickness Year: 2021